BAR-501 is primarily used in research settings for its potential therapeutic effects in inflammatory and metabolic disorders. It acts as a dual agonist targeting specific nuclear receptors involved in regulating inflammation, lipid metabolism, and glucose homeostasis. Due to its ability to modulate these pathways, BAR-501 is being investigated for applications in non-alcoholic steatohepatitis (NASH), type 2 diabetes, and other conditions linked to chronic inflammation and metabolic dysfunction. Its design allows for improved tissue selectivity, which may reduce side effects commonly associated with broader receptor activation. Currently, it remains a preclinical or early-stage development compound, serving as a tool compound to validate pharmacological targets and assess efficacy in disease models.